RxDoctor Payments Data

Madankumar Raj, MD

Pain Medicine · Great Neck, NYNPI 1528029162

Payments from drug & device makers

$4,298in general payments, 2019–2025

Across 186 payments — averaging $23.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$1K
  • Boston Scientific$460
  • Kowa Pharmaceuticals America, Inc.$457
  • AbbVie$415
  • Scilex Pharmaceuticals Inc.$379
  • Nevro Corp.$261
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$4,298100%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,298 in reported general payments places this provider in the 70th percentile of 503 pain medicine providers in New York.

See all pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$172,877
Medicare patients
151
Services billed
2,434

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate36$21,261
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen354$17,966
OxycontinOxycodone Hcl27$14,809
MovantikNaloxegol Oxalate28$12,804
NucyntaTapentadol Hcl11$9,729
Oxycodone Hcl604$9,616
Morphine Sulfate ErMorphine Sulfate364$6,354
Topiramate ErTopiramate11$4,965
Naloxone Hcl49$3,296
Gabapentin294$2,496
Lidocaine29$2,123
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen137$1,573
Fentanyl13$1,483
Naproxen Sodium11$1,336
Pregabalin73$1,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta$1,216$30,99147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 503 pain medicine providers in New York.

Other pain medicine in Great Neck

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →